Clinical Trial Search

Primary: Time to First Relapse of Any Mood Episode During the Double-Blind Treatment Period — NA; NA; NA; NA days — p=0.5745

Primary: Composite of Mortality or Need for ICU Admission or Ventilator Use — 2; 0 Participants

Primary: Decrease in Morphine Equivalent Dose (MED) — 85; 105 Participants

Primary: Randomization — 0; 0 Participants

Primary: Endogenous Glucose Production — .66 [mg/(kgxmin)]

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 — -74.45; -41.43 percent change — p=<0.001

Primary: Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and…

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 5.8; 18.0; 44.2…

Primary: Number of Subjects With the Absence of Particular Events as Adjudicated by the CEC Through 1-month Post Procedure: — 43 participants

Primary: Change in Cough Severity as Measured by the Cough Visual Analog Scale (VAS) — -50.67 units on a scale — p=0.108

Primary: Subjects Free From Procedure/Device Related Serious Adverse Events (SAEs) — 115 Participants

Primary: Binge Eating Episodes - Loss of Control — 0.212 episodes — p=0.066

Primary: Percentage of Patients Achieving Clinical Remission at Week 54 — 127; 30 Participants — p=<0.0001

Primary: Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative — -8.26; -8.40; -7.16; -8.20 mmHg

Primary: Acne Scarring Improvement — 4; 4 score on a scale